Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) said on Thursday that it has launched its butalbital acetaminophen and caffeine (BAC) capsule in 50mg/300mg/40mg in the United States for the treatment of tension headache (migraine).
It comes after the company received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for BAC.
US sales of BAC capsule 50mg/300mg/40mg were approximately USD40m for the 12 months ending 31 March 2020, according to IQVIA.
Mayne Pharma markets more than 60 generic and specialty branded pharmaceuticals in the US.
Nivagen Pharmaceuticals Closes USD 16m Growth Equity Financing from Telegraph Hill Partners
Rising Pharmaceuticals to Support Global Clinical Trial Conducted by the CROWN Collaborative
Natera announces receipt of positive Medicare coverage for Prospera DNA test
Lannett Company reports third quarter fiscal 2020 financial results
Henlius receives EU GMP certificate for HLX02
Fujifilm expands production of influenza antiviral drug Avigan for COVID-19
USFDA grants final approval to Cipla's Albuterol Sulfate Inhalation Aerosol
FDA approves generic albuterol inhaler for treating bronchospasm
Hikma receives favourable ruling in generic Vascepa patent suit from US Court
Flexipharm Austrading unveils first vial and generic Methylthioninium Chloride for NHS hospitals